Made by Orexigen, the drug, if approved on January 31, 2011, will be marketed under the name Contrave. The diet pill is a combination of two drugs which have been on the market for roughly 25 years – Bupropion – also known as Wellbutrin and Naltraexone. Wellbutrin is commonly prescribed for the treatment of depression and smoking cessation. Naltrexone is used to treat opioid and alcohol addictions.
READ MORE Pharmaceutical LEGAL NEWS
"I am most distressed about this particular adverse effect," committee member Jules Hirsch, MD, of Rockefeller University in New York City told WebMD. "There needs to be very, very careful attention if this drug is approved." Committee members also expressed concern over the lack of long-term safety data on Contrave.